87 related articles for article (PubMed ID: 16963424)
1. [Analysis of diffuse large B-cell lymphoma heterogeneity based on coupled two-way clustering].
Li L; Li X; Chen YH; Guo Z; Jiang W; Zhagn RJ; Rao SQ
Yi Chuan; 2006 Sep; 28(9):1129-34. PubMed ID: 16963424
[TBL] [Abstract][Full Text] [Related]
2. Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering.
Zhang W; Li L; Li X; Jiang W; Huo J; Wang Y; Lin M; Rao S
BMC Genomics; 2007 Sep; 8():332. PubMed ID: 17888167
[TBL] [Abstract][Full Text] [Related]
3. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.
Culpin RE; Proctor SJ; Angus B; Crosier S; Anderson JJ; Mainou-Fowler T
Int J Oncol; 2010 Aug; 37(2):367-76. PubMed ID: 20596664
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
[TBL] [Abstract][Full Text] [Related]
5. Microarray-based classification of diffuse large B-cell lymphoma.
Poulsen CB; Borup R; Nielsen FC; Borregaard N; Hansen M; Grønbaek K; Møller MB; Ralfkiaer E
Eur J Haematol; 2005 Jun; 74(6):453-65. PubMed ID: 15876249
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
7. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis.
Rossi D; Gaidano G
Hematology; 2002 Aug; 7(4):239-52. PubMed ID: 14972786
[TBL] [Abstract][Full Text] [Related]
8. Pathway-based analysis of the hidden genetic heterogeneities in cancers.
Zhao X; Zhong S; Zuo X; Lin M; Qin J; Luan Y; Zhang N; Liang Y; Rao S
Genomics Proteomics Bioinformatics; 2014 Feb; 12(1):31-8. PubMed ID: 24462714
[TBL] [Abstract][Full Text] [Related]
9. Coupled two-way clustering analysis of gene microarray data.
Getz G; Levine E; Domany E
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12079-84. PubMed ID: 11035779
[TBL] [Abstract][Full Text] [Related]
10. Randomized maps for assessing the reliability of patients clusters in DNA microarray data analyses.
Bertoni A; Valentini G
Artif Intell Med; 2006 Jun; 37(2):85-109. PubMed ID: 16720093
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
13. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas.
Mircean C; Tabus I; Kobayashi T; Yamaguchi M; Shiku H; Shmulevich I; Zhang W
Int J Oncol; 2004 Mar; 24(3):497-504. PubMed ID: 14767533
[TBL] [Abstract][Full Text] [Related]
14. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
15. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
16. A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.
Michaelsen TY; Richter J; Brøndum RF; Klapper W; Johnsen HE; Albertsen M; Dybkær K; Bøgsted M
Blood Adv; 2018 Jul; 2(13):1542-1546. PubMed ID: 29967255
[TBL] [Abstract][Full Text] [Related]
17. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
18. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
Wright G; Tan B; Rosenwald A; Hurt EH; Wiestner A; Staudt LM
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9991-6. PubMed ID: 12900505
[TBL] [Abstract][Full Text] [Related]
19. Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Maesako Y; Uchiyama T; Ohno H
Cancer Sci; 2003 Sep; 94(9):774-81. PubMed ID: 12967475
[TBL] [Abstract][Full Text] [Related]
20. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas.
Muris JJ; Ylstra B; Cillessen SA; Ossenkoppele GJ; Kluin-Nelemans JC; Eijk PP; Nota B; Tijssen M; de Boer WP; van de Wiel M; van den Ijssel PR; Jansen P; de Bruin PC; van Krieken JH; Meijer GA; Meijer CJ; Oudejans JJ
Br J Haematol; 2007 Jan; 136(1):38-47. PubMed ID: 17062006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
